arrow
T

Tadepally Lakshmikanth

karolinska institutet
H指数:26
被引数:5,838

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

作者更正:构象选择性PI3Kδ抑制剂roginolisib在晚期或转移性癌症患者中的研究,包括转移性眼黑色素瘤:首次人体临床试验

2026-11-130
OAAI
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

在晚期或转移性癌症患者中具有构象选择性的PI3Kδ抑制剂roginolisib的临床试验:首次人体试验,包括转移性葡萄膜黑色素瘤

2026-10-090
OAAI
A human pan-disease blood atlas of the circulating proteome

循环蛋白质组的人类泛疾病血液图谱

SCIENCE
IF45.8
2025-12-183
PRE
Microbiome-derived bile acid signatures in early life and their association with islet autoimmunity

微生物组衍生的胆汁酸特征与早期生命中的胰岛自身免疫相关性

2025-12-030
OAAI
Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies
2024-10-230
OAAI
Systems-level immunomonitoring in children with solid tumors
2024-03-220
PRE
Gut bacteria at 6 months of age are associated with immune cell status in 1-year-old children
2023-12-072
OA
First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
2021-12-013
OA
Integration of molecular profiles in a longitudinal wellness profiling cohort

纵向健康概况队列中分子概况的整合

2020-09-0873
OAAI